The next blockbuster in Cardiology? Heart failure is one of the most common causes of death in the western world. A drug that possibly could effect the underlying cause of the disease could both save thousands of lifes and be a blockbuster for the company that develops it. If that is what we have remains to be seen…
We are looking for a non-executive chairperson of the board for a privately held Swedish, clinical stage biopharmaceutical company. Based on ground-breaking research from Karolinska Institute they develop novel drugs to treat heart failure.
The chairperson is someone with cardiovascular drug development experience, knows how to operate a small company and has a track record of licensing drug projects either on the buying or selling side.
Want to know more? Contact me and register here!